Evommune, Inc.
EVMNFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Evommune, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Source: Evommune, Inc. — 10-K filed Mar 5, 2026
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 2 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 24, 2026.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Evommune, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-06-22 · Drew Janice Suzann: Larger than all 8 other insider sales of Common Stock on file. SEC filing
Independent insiders buying near the same time
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-22 | Patel Jeegar Pravinkumar · Chief Scientific Officer | Common Stock | S — Open market or private sale | −1,488 | 22.50 | SEC filing |
| 2026-06-22 | Pena Luis C. · President & CEO | Common Stock | S — Open market or private sale | −7,438 | 22.71 | SEC filing |
| 2026-06-22 | Drew Janice Suzann · Chief of Dev. Operations | Common Stock | S — Open market or private sale | −20,000 | 22.63 | SEC filing |
| 2026-06-02 | Cohen David E · Director | Common Stock | S — Open market or private sale | −600 | 21.38 | SEC filing |
| 2026-06-02 | Cohen David E · Director | Common Stock | S — Open market or private sale | −5,456 | 20.21 | SEC filing |
| 2026-06-01 | Pena Luis C. · President & CEO | Common Stock | S — Open market or private sale | −16,787 | 22.74 | SEC filing |
| 2026-06-01 | Patel Jeegar Pravinkumar · Chief Scientific Officer | Common Stock | S — Open market or private sale | −16,687 | 22.74 | SEC filing |
| 2026-05-28 | Carver Kyle · Chief Financial Officer | Common Stock | S — Open market or private sale | −18,175 | 22.84 | SEC filing |
Showing 8 of 14 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-22 | Drew Janice Suzann · Chief of Dev. Operations | Common Stock | M — Exercise or conversion of derivative security | +16,161 | SEC filing |
| 2026-06-22 | Drew Janice Suzann · Chief of Dev. Operations | Common Stock | M — Exercise or conversion of derivative security | +3,839 | SEC filing |
| 2026-06-22 | Drew Janice Suzann · Chief of Dev. Operations | Employee Stock Option (Right to Buy) | M — Exercise or conversion of derivative security | −16,161 | SEC filing |
| 2026-06-22 | Drew Janice Suzann · Chief of Dev. Operations | Employee Stock Option (Right to Buy) | M — Exercise or conversion of derivative security | −3,839 | SEC filing |
| 2026-06-22 | Patel Jeegar Pravinkumar · Chief Scientific Officer | Employee Stock Option (Right to Buy) | M — Exercise or conversion of derivative security | −1,488 | SEC filing |
| 2026-06-22 | Patel Jeegar Pravinkumar · Chief Scientific Officer | Common Stock | M — Exercise or conversion of derivative security | +1,488 | SEC filing |
| 2026-06-02 | KIRSCH ARTHUR S · Director | Stock Option (Right to buy) | A — Grant, award, or other acquisition | +15,673 | SEC filing |
| 2026-06-02 | Cohen David E · Director | Stock Option (Right to buy) | A — Grant, award, or other acquisition | +15,673 | SEC filing |
Showing 8 of 26 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.